REG - HeiQ PLC - Issue of Equity

HeiqAnnouncement

24/02/2022 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220224:nRSX7576Ca&default-theme=true

RNS Number : 7576C  HeiQ PLC  24 February 2022

24 February 2022

 

HeiQ Plc

("HeiQ" or "the Company")

 

Issue of Equity and Total Voting Rights

 

HeiQ Plc (LSE: HEIQ), a Swiss IP innovator and established global brand in
materials and textile innovation which operates in high-growth markets,
announces the issuance of 347,552 new ordinary shares of £0.30 each in the
Company ("New Shares"). These shares have been allotted to the vendors of Life
Material Technologies Limited ("Life") to satisfy a closing working capital
adjustment in connection with the Company's acquisition of Life in June 2021,
further details of which are contained within the Company's announcement dated
15 June 2021. As previously announced, additional earn-out consideration may
be payable to Life in due course through the issuance of new ordinary shares
and a further announcement will be made in due course.

 

Applications have been made to the London Stock Exchange and FCA for the New
Shares to be admitted to the standard segment of the Official List and also
admitted to trading on the London Stock Exchange ("Admisison").

 

Admission is expected to become effective on 25 February  2022.

 

The shares will be issued fully paid and will rank pari passu in all respects
with the existing issued ordinary shares of the Company.

 

Total Voting Rights

Following the issue and allotment of the New Shares the Company has
130,931,088 Ordinary Shares in issue. The Company holds no Ordinary Shares in
treasury, and therefore the total number of voting rights in the Company
is 130,931,088. This figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information, please contact:

 

 HeiQ Plc                                        +41 56 250 68 50

 Carlo Centonze (CEO)
 Cenkos Securities plc (Joint Broker)            +44 (0) 207 397 8900

 Stephen Keys / Callum Davidson
 SEC Newgate (Media Enquiries)                   +44 (0) 20 3757 6882

 Elisabeth Cowell / Robin Tozer / Megan Kovach   HeiQ@s (mailto:HeiQ@secnewgate.co.uk) ecnewgate (mailto:HeiQ@secnewgate.co.uk)
                                                 .co.uk (mailto:HeiQ@secnewgate.co.uk)

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by
innovating the materials people use every day. HeiQ has strong IP which is at
the forefront of global technology in the $10 billion antimicrobial fabrics
market, $24 billion textile chemicals market, the $50 billion probiotics
market and the $150 billion man-made fibers market. It has also moved into the
medical device, healthcare and hygiene coatings markets, to help make
hospitals and healthcare environments more hygienic. HeiQ aims to deliver
growth for its shareholders through a combination of increased sales of its
core products and by entering additional lucrative markets through disruptive
innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance
technologies in the market today, which cool, warm, dry, repel, purify, and
destroy viruses. Since 2005, HeiQ has developed over 200 technologies in
partnership with 300 major brands and it has a significant R&D pipeline
containing over 50 projects. The Company has won multiple awards and gained a
strong reputation for the ESG & sustainable downstream effect of its
innovations. HeiQ is the only company to have won the Swiss Technology award
twice. It has also won the Swiss Environmental award with an innovation that
saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for
partners, delivers scaled up manufacturing from its sites across the world and
helps partners market the product to end consumers - aiming for lab to
consumer in months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESEEFLLEESEIE